4.8 Article

RIPK1 mediates axonal degeneration by promoting inflammation and necroptosis in ALS

Journal

SCIENCE
Volume 353, Issue 6299, Pages 603-608

Publisher

AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/science.aaf6803

Keywords

-

Funding

  1. National Institute of Neurological Disorders and Stroke, NIH [1R01NS082257]
  2. National Institute on Aging, NIH [1R01AG047231]
  3. National Science and Technology Major Project of China [2014ZX09102001-002]
  4. State Key Program of National Natural Science of China [31530041]
  5. National Institute of Allergy and Infectious Diseases [2RO1AI075118]
  6. European Research Council [323040]
  7. Daiichi Sankyo Foundation of Life Science (Japan)
  8. Nakatomi Foundation (Japan)
  9. Mochida Memorial Foundation for Medical and Pharmaceutical Research (Japan)
  10. Japan Society for the Promotion of Science (Japan)
  11. National Multiple Sclerosis Society
  12. National Multiple Sclerosis Society Career Transition Award
  13. Huazhong University of Science and Technology, Wuhan, China
  14. European Research Council (ERC) [323040] Funding Source: European Research Council (ERC)

Ask authors/readers for more resources

Mutations in the optineurin (OPTN) gene have been implicated in both familial and sporadic amyotrophic lateral sclerosis (ALS). However, the role of this protein in the central nervous system (CNS) and how it may contribute to ALS pathology are unclear. Here, we found that optineurin actively suppressed receptor-interacting kinase 1 (RIPK1)-dependent signaling by regulating its turnover. Loss of OPTN led to progressive dysmyelination and axonal degeneration through engagement of necroptotic machinery in the CNS, including RIPK1, RIPK3, and mixed lineage kinase domain-like protein (MLKL). Furthermore, RIPK1- and RIPK3-mediated axonal pathology was commonly observed in SOD1(G93A) transgenic mice and pathological samples from human ALS patients. Thus, RIPK1 and RIPK3 play a critical role in mediating progressive axonal degeneration. Furthermore, inhibiting RIPK1 kinase may provide an axonal protective strategy for the treatment of ALS and other human degenerative diseases characterized by axonal degeneration.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available